Cargando…
Pharmacological inhibition of TAK1 prevents and induces regression of experimental organ fibrosis
Multiorgan fibrosis in systemic sclerosis (SSc) accounts for substantial mortality and lacks effective therapies. Lying at the crossroad of TGF-β and TLR signaling, TGF-β–activated kinase 1 (TAK1) might have a pathogenic role in SSc. We therefore sought to evaluate the TAK1 signaling axis in patient...
Autores principales: | Bale, Swarna, Verma, Priyanka, Yalavarthi, Bharath, Scarneo, Scott Arthur, Hughes, Philip, Amin, M. Asif, Tsou, Pei-Suen, Khanna, Dinesh, Haystead, Timothy A.J., Bhattacharyya, Swati, Varga, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443806/ https://www.ncbi.nlm.nih.gov/pubmed/37306632 http://dx.doi.org/10.1172/jci.insight.165358 |
Ejemplares similares
-
Deficiency of inhibitory TLR4 homolog RP105 exacerbates fibrosis
por: Wang, Wenxia, et al.
Publicado: (2022) -
TAK1 regulates the tumor microenvironment through inflammatory, angiogenetic and apoptotic signaling cascades
por: Scarneo, Scott A., et al.
Publicado: (2020) -
Delineation of the distinct inflammatory signaling roles of TAK1 and JAK1/3 in the CIA model of rheumatoid arthritis
por: Freeze, Robert, et al.
Publicado: (2023) -
Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice
por: Scarneo, Scott A., et al.
Publicado: (2019) -
Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion
por: Scarneo, Scott A., et al.
Publicado: (2018)